A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy
Open Access
- 1 January 2010
- journal article
- research article
- Published by Springer Nature in Molecular Cancer
- Vol. 9 (1), 69
- https://doi.org/10.1186/1476-4598-9-69
Abstract
The endothelin system is implicated in the pathogenesis of melanoma. We evaluated the effects of bosentan - a dual endothelin receptor antagonist - in patients receiving first-line dacarbazine therapy for stage IV metastatic cutaneous melanoma in a phase 2, proof-of-concept study.Keywords
This publication has 26 references indexed in Scilit:
- Cutaneous melanoma in the era of molecular profilingThe Lancet, 2009
- Melanoma epidemiology and trendsClinics in Dermatology, 2009
- Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2008
- Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study GroupJournal of Clinical Oncology, 2008
- Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study GroupJournal of Clinical Oncology, 2006
- Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2005
- Final Version of the American Joint Committee on Cancer Staging System for Cutaneous MelanomaJournal of Clinical Oncology, 2001
- Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant MelanomaJournal of Clinical Oncology, 2000
- Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic MelanomaJournal of Clinical Oncology, 1999
- Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.Journal of Clinical Oncology, 1998